News

BioAlliance Pharma announces Phase I trial for Fentanyl Lauriad® and the submission of a Clonidine Lauriad® Phase II clinical trial application

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®. This clinical trial will evaluate the plasma pharmacokinetic parameters of Fentanyl Lauriad® in healthy volunteers. It is expected to…read more →

BioAlliance Pharma announces that the civil action filed by Eurofins in the United States is rejected

BioAlliance Pharma SA (Euronext Paris – BIO) announces today that the American District Judge has granted the motion to dismiss of BioAlliance Pharma and one of its executive in response to the civil action filed by Eurofins. Eurofins filed an appeal. In 2008, Eurofins Pharma US Holding Inc. and one of its affiliates Viralliance Inc (“Eurofins”) had filed a civil…read more →

BioAlliance Pharma makes four presentations at the 49th ICAAC meeting

including three phase III study results with miconazole Lauriad® and one with its integrase inhibitor BioAlliance Pharma has attended the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco to present results on miconazole Lauriad® and anti-integrase inhibitor. The results of a phase III study with miconazole Lauriad® mucoadhesive buccal tablets (MBT) that demonstrate noninferiority to…read more →

BioAlliance Pharma to present at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine

(Bergen, Norway, August 31 to September 2, 2009) BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will present its nanoparticle technology and the latter’s advantages in therapeutic applications at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine, to…read more →

BioAlliance Pharma announces positive preliminary pivotal phase III results in herpes labialis with acyclovir Lauriad®

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, is pleased today to announce positive preliminary results in its LIP phase III pivotal study (Lauriad® Immunocompetent Patients Study ). This multicenter randomized, double-blind, placebo controlled study compared the efficacy and safety of a single dose acyclovir Lauriad® 50mg…read more →

Consolidated accounts for the first half of 2009

• Loramyc® sales triple • submission of a marketing authorization application for Setofilm® in Europe • submission of a new drug application for Loramyc® in the USA • significant progress in the supportive care portfolio • OSEO funding validates the company’s innovations BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer…read more →

Loramyc® obtains Marketing Authorization in Switzerland

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that Loramyc® has obtained Marketing Authorization in Switzerland for the treatment of oropharyngeal candidiasis in immunocompromised patients (mainly cancer and AIDS patients with oral opportunistic infections). “This approval represents an important milestone for Loramyc® which is now…read more →

FDA Accepts Drug Application for Miconazole Lauriad® (Loramyc®) to Treat Oropharyngeal Candidiasis

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive…read more →

BioAlliance Pharma submits clinical trial new drug application

and announces results of its July 27th 2009 General Assembly Meeting BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the submission of a Fentanyl Lauriad® clinical trial application to the French Drug Agency (AFSSaPS) and its approval by the Ethics Committee (Comité de Protection des…read more →

Turnover for Q2 2009

sustained sales growth and an NDA for Loramyc® in the USA BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it had generated a consolidated turnover of €1.5 million during the second quarter of 2009. Turnover Quarterly sales of Loramyc® in France continued to grow…read more →

BioAlliance Pharma signs a co-promotion agreement with Lundbeck for in-hospital prescription of the antidepressant Seroplex®

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the signature of a 2009 co-promotion agreement with Lundbeck for the latter’s Seroplex® antidepressant. BioAlliance Pharma will co-promote Seroplex® to its core healthcare partners (notably oncologists, radiotherapists and hematologists) as part of a comprehensive approach to patient…read more →

BioAlliance Pharma obtains european approval for Loramyc® tablet embossing and extension of its shelf life to 36 months

BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced Europe-wide approval for embossing its Loramyc® mucoadhesive buccal tablet, developed for the treatment of oropharyngeal candidiasis. The embossing process has thus been approved under the Mutual Recognition Procedure; it was first required for the US market, where BioAlliance…read more →

Combined Extraordinary and Ordinary General Meeting on July 27th 2009

Procedures for obtaining preparatory documents BioAlliance Pharma’s shareholders are invited to attend the Combined Extraordinary and Ordinary General Meeting to be held at 10.00 am on July 27th 2009 at the company’s head office (49 Boulevard du Général Martial Valin, F-75015 Paris, France). The official notice of the Meeting will be published in the French Republic’s Bulletin des Annonces Légales…read more →

BioAlliance Pharma submits loramyc® NDA to us FDA

and announces a general shareholders’ meeting to amend its by-laws BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to the treatment of cancer and AIDS patients and supportive care, today announced the submission of its New Drug Application (NDA) to the United States Food and Drug Administration (FDA), as planned, for the approval of Loramyc®, Mucoadhesive Buccal Tablets (MBT),…read more →

Upcoming BioAlliance Pharma’s presentations at international Conferences on infectious diseases and oncology

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to therapies and supportive care for cancer and AIDS patients, today announced its scientific communications at upcoming international conferences on infectious diseases and oncology: Loramyc®, indicated for fungal infections in immune-compromised patients with HIV or cancer The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting May 29 to June…read more →